JP2023542212A5 - - Google Patents
Info
- Publication number
- JP2023542212A5 JP2023542212A5 JP2023518392A JP2023518392A JP2023542212A5 JP 2023542212 A5 JP2023542212 A5 JP 2023542212A5 JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023542212 A5 JP2023542212 A5 JP 2023542212A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20198050.5 | 2020-09-24 | ||
| EP20198050 | 2020-09-24 | ||
| EP20201583.0 | 2020-10-13 | ||
| EP20201583 | 2020-10-13 | ||
| EP21172627 | 2021-05-07 | ||
| EP21172627.8 | 2021-05-07 | ||
| PCT/EP2021/075995 WO2022063803A1 (en) | 2020-09-24 | 2021-09-22 | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542212A JP2023542212A (ja) | 2023-10-05 |
| JPWO2022063803A5 JPWO2022063803A5 (https=) | 2024-09-30 |
| JP2023542212A5 true JP2023542212A5 (https=) | 2024-09-30 |
Family
ID=78000677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518392A Pending JP2023542212A (ja) | 2020-09-24 | 2021-09-22 | Ｔ細胞二重特異性抗体に関連する有害作用の予防又は緩和 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220088195A1 (https=) |
| EP (1) | EP4216998A1 (https=) |
| JP (1) | JP2023542212A (https=) |
| KR (1) | KR20230074146A (https=) |
| CN (1) | CN116322691A (https=) |
| AU (1) | AU2021350075A1 (https=) |
| BR (1) | BR112023005399A2 (https=) |
| CA (1) | CA3193478A1 (https=) |
| IL (1) | IL300543A (https=) |
| MX (1) | MX2023003133A (https=) |
| TW (1) | TW202228773A (https=) |
| WO (1) | WO2022063803A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| JP2025539760A (ja) * | 2022-11-15 | 2025-12-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合分子 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| MX375359B (es) | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| JP6553069B2 (ja) * | 2013-11-07 | 2019-07-31 | メモリアル スローン ケタリング キャンサー センター | 抗ｗｔ１／ｈｌａ二重特異性抗体 |
| JP6464255B2 (ja) | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| SG11202005632SA (en) * | 2017-12-21 | 2020-07-29 | Hoffmann La Roche | Antibodies binding to hla-a2/wt1 |
| EP3863644A4 (en) * | 2018-10-12 | 2022-10-05 | Jeanmarie Guenot | CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES |
-
2021
- 2021-09-22 CN CN202180065376.9A patent/CN116322691A/zh active Pending
- 2021-09-22 IL IL300543A patent/IL300543A/en unknown
- 2021-09-22 CA CA3193478A patent/CA3193478A1/en active Pending
- 2021-09-22 WO PCT/EP2021/075995 patent/WO2022063803A1/en not_active Ceased
- 2021-09-22 AU AU2021350075A patent/AU2021350075A1/en active Pending
- 2021-09-22 MX MX2023003133A patent/MX2023003133A/es unknown
- 2021-09-22 EP EP21782915.9A patent/EP4216998A1/en active Pending
- 2021-09-22 JP JP2023518392A patent/JP2023542212A/ja active Pending
- 2021-09-22 KR KR1020237009954A patent/KR20230074146A/ko active Pending
- 2021-09-22 BR BR112023005399A patent/BR112023005399A2/pt unknown
- 2021-09-23 TW TW110135298A patent/TW202228773A/zh unknown
- 2021-09-24 US US17/448,729 patent/US20220088195A1/en active Pending